This paper presents an approach to evaluating the potential supply chain benefits of adopting continuous processing technologies for a diverse set of pharmaceutical products. The approach integrates upstream 'continuous' processing considerations for the production of active ingredients and final product formulation, with the downstream implications for packing and distribution. Currently, these upstream and downstream operations largely operate as decoupled operations with independent coordination and governance mechanisms, and the approach presented in this paper identifies opportunities for more case-specific integrated end-to-end supply chains enabled by continuous flow technologies. Three specific product (and corresponding processing technology) case studies are used to demonstrate the utility of the approach in assessing the supply network and system integration opportunities that emerge from the continuous processing of pharmaceutical products.
INTRODUCTION
In many industries, supply chains have become 'disaggregated', with activities spread across multiple firms and locations, with individual manufacturing sites increasingly geographically distributed. In Pharmaceuticals, this specialisation has been heavily influenced by the separation of unit operations between the discrete steps of Active Pharmaceutical Ingredient (API), Primary Product Formulation, Secondary Pack Processing, and Distribution activities. Indeed within each of these manufacturing supply chain stages, the predominance of batch processing models has meant that existing pharmaceutical supply chains operate in a high inventory, slow response environment. Traditionally, manufacturing supply network design has involved integrating these disaggregation of value networks has been analysed from an emerging technology context [10] ; the healthcare context providing radically different patient-centric supply chain models and potentially novel business models.
From a theoretical perspective, supply chain analysis and design requires a focal firm perspective of an extended network of firms across a defined product category. However, the optimum configuration of these increasingly complex and fragmented networks is particularly challenging where there are 'multiple tiers' of partner firms, spanning component and intermediate goods supply, presenting a multitude of options on location and partnering models [11] , [12] . These supply networks comprise of semi-independent sub-systems that have then become part-disconnected with independent governance mechanisms. These sub-systems can, over time frustrate the operation of integrated outcome based supply chains. For these complex multi-tier supply networks, the more holistic approach presented here considers the industrial system design activity as an integrating process that spans the discrete sub-systems that make up the end-to-end supply chain.
NETWORK SYSTEMS ANALYSIS AND INTEGRATION OF SUB-SYSTEMS
The methodology that is presented here builds on cross-sector observations of complex multi-tier supply networks where sub-systems have evolved as discrete entities [12] , and an underlying premise that a whole systems perspective can support a re-examination of end-to-end network design. A re-configuration of the network requires identification of the drivers of, and interactions between, the main sub-systems in these complex, multi-tier supply networks. The attractiveness of applying the sub-systems integration approach will arise in multi-tier supply networks where the production of intermediate goods, as discrete sub-systems, has emerged as a mechanism for the effective organisation of the current industrial system. In Consumer Electronics for example, global scale contract manufacturers now dominate the sector, supplying key components and/or providing final assembly operations. In Aerospace, major component supply chains have emerged that operate as discrete entities; the UK for example is No.2 globally in aerospace manufacture without major final assembly.
Intermediate goods supply chains are also prevalent in the textile sector where opportunities for supply network development involve re-integration of discrete operations, with some manufactures considering closed loop supply chains to optimise resource re-use. These reconfiguration options are invariably driven by technology changes.
However, in most sectors sub-systems operate as independent units targeting internal efficiencies, functioning as silos of activity, mirroring the functional units seen in large organisations. This internal sub-system focus can work to the detriment of the end-to-end supply network. In highly regulated environments, regulation can inadvertently 'lock-in' this structural development and frustrate end-to-end supply chain optimisation. In Pharmaceuticals, the sub-system of clinical supply often imposes production process and consequent regulatory constraints for the commercial supply chain.
The reconnecting of semi-isolated sub-systems presents opportunities for an end-to-end supply network perspective, connecting upstream and downstream elements. This approach to supply network integration and optimisation can inform the product-process technology agenda. Alternative production processing models would target system outcomes that aim to address sub-system constraints, redefining supply network drivers of network performance. Examples of alternative processing models that might support more 'flow-through' end-to-end operations include continuous-processing and crystallisation in previously batch-process-oriented Pharma, additive manufacturing in engineering component manufacture that replaces traditional subtractive processes (e.g. aero-engine casings are now manufactured at the point of final assembly rather than being produced in three separate locations before being shipped to the assembly site), and late product post-dosing finishing models that enable more near-market supply (e.g. in FMCG post dosing used for variant production with reduced lead times; industrial ceramics continuous inkjet variant production in Europe to satisfy SKU proliferation demands [1] ). Each of these alternative supply chain models have required significant technology breakthroughs to enable a broader industrial systems optimisation agenda, enabling radically different product quality and/or flexibility (volume, variety) opportunities, potentially enabling previously elusive markets to be served economically.
In this research, we develop an approach to evaluate the system level business opportunities that arise from the continuous processing of pharmaceutical products. To demonstrate the utility of the approach, the three different cases are considered to evaluate the relative benefits of continuous processing.
METHODOLOGY DEVELOPMENT -PHARMA CONTEXT
While evidence exists for continuous processing delivering financial benefits (mainly for single-purpose plants), these studies have largely been focused at the production and plant level [13] , [14] , [15] , [16] with the overall business case in each case lacking an end-to-end supply network assessment. These case studies are discussed briefly later in this section.
The approach to network design and systems integration extends prior work on industrial systems analysis and supply chain mapping techniques [10] , [11] , [17] . It involves identifying the drivers of, and interactions between, the main sub-systems across the supply network. System boundaries are extended to encompass the end-user, and used to inform potential sub-system trade-offs. A key requirement involves 'technology experts' to evaluate alternative supply network configuration models.
From an end-to-end supply network perspective, four proposed stages of analysis are summarised below;
i.
Identifying barriers and opportunities to adopting alternative product-process technologies Barriers may be real or perceived and arise from combinations of socio-political, technical and regulatory factors.
Despite such barriers to adoption, there is growing evidence, within industrial setting, that firms are moving towards significant adoption of continuous processing, some examples of which are outlined in table 1.
Table 1. Summary of companies with significant investments in continuous processing
In addition, the academic literature has also reported studies where continuous processing has been
shown to have an advantage over batch, in terms of process, economics and volumes.
In their study comparing continuous and batch reactors with respect to nitration and hydrogenation reactions, Calabrese et al. [13] observed a drastic reduction in the hydrogenation reaction, from 10h to < In terms of an end-to-end assessment, volume and complexity are two key discriminating variables (in many product sectors/categories) that can influence supply network design [25] . In the context of this study, figure 1 sets out, at a conceptual level the opportunity in the batch-continuous context for particular processing models, e.g.
Position A on the chart focuses on unmet patient needs and affordability for low volume and high variant products. In this space, alternative processing models may be used to serve existing markets more effectively or those that have been previously considered uneconomical to serve (delivering unmet end-user needs) driven by new capabilities that create new markets.
Personalised medicines or niche product markets exemplify patient populations where advances in diagnostics, information technologies and digitisation, are enabling more disaggregated value network models. The argument here is that micro-continuous processing may offer solutions and this is being actively pursued by several research centres e.g. CMAC.
 Position B at the centre captures the space where both batch and continuous processing could feasibly work. Here, batch processing may still retain cost advantages over continuous at certain volumes and SKU mixes. ii.
Sub-system identification and analysis; comparison with an end-to-end systems perspective
Current-state supply and value network mapping techniques are used to define the existing subsystems and the drivers/design factors that predominate in each sub-system. A schematic representation of a typical 'current-state' processing model for pharmaceutical production is presented in figure 2 . In reality, this process model will vary case-by-case with some processing activities not required and additional processing steps necessary. Once the current state has been mapped for a specific case, alternative continuous technology processing options and their technology readiness levels may be assessed. An end-to-end network performance analysis is then used to define overall system metrics in order to re-examine these semi-independent sub-systems, challenging the current state configuration design parameters and trade-offs being made. business model innovations are evaluated. Alternatives process and production technologies may be based on emerging technologies or technologies that are still yet to be fully proven or developed but where a supply network assessment identifies system benefits that would emerge from a more 'flowthrough' operation.
In Pharmaceuticals, emerging technologies may be primary production technology based, such as continuous processing and crystallisation of APIs, or secondary continuous processing of final product formulations, or driven by novel routes to market driven by next generation diagnostics. These alternative scenarios may support very different scale production operations, i.e. rather than the large one-size fits all batch plants of today, consideration of dispersed, close-to-market, low-scale integrated plants may be possible through new production technologies. Alternative downstream supply models might also be possible due to advances in patient diagnostics, product re-ordering models or direct replenishment, enabled by e-commerce-based last-mile supply chains. In practice, scenarios depend on various disruptive influences that challenge the current value network model and introduce new possibilities to product or product-service models.
iv. Systems Analysis Analytical Framework
Finally, an end-to-end supply network systems analysis is undertaken. This process evaluates the alternative scenarios under consideration and how they might redefine existing sub-systems as part of an integrated systems/network re-configuration agenda. The approach involves the assessment of potential benefits of promising scenarios, as a 'delta' analysis on the current state against key system metrics. Whereas system benefits may accrue, the value proposition in making the transformation for key supply network partners is assessed from a business context. For example, the potential impact on revenue, margin, inventory reduction etc, against the investments required, and the technological feasibility of the identified disrupted scenario. These elements of the evaluation are incorporated into a total systems/network analytical framework.
In this paper, we set out the criteria used in each stage of the analysis process, and demonstrate the application of the analytical framework for three pharmaceutical products where 'alternative' continuous processing technologies are being considered.
The Pharmaceutical sector was chosen as it faces multiple challenges; affordability of drugs that question the viability of current operating models, ageing populations that require new approaches to patient care, and major technology advances in therapeutics and production technologies, changes that have the potential to generate very different supply network configurations with increasingly distributed information flows and revenue models [1] , [26] . The sector also exhibits the criteria of a multi-tier supply network with very well established and independently managed sub-systems of active production, formulation, and final pack, with extended distribution models. Material resource efficiency end-to-end is poor with low patient compliance, compounded by waste in the production process, with moderate production process quality performance (typically 3 sigma). From a product life cycle perspective, Clinical trial supply chains are also typically managed separately from the full-scale commercial supply chains. Regulatory and governance frameworks map these separate and established batchprocess operating models. National governments are increasingly reluctant to accept the cost of new drugs whilst the major primes are managing a more fragmented product portfolio as new technologies are driving smaller volume production runs targeting more niche markets. At a network systems level, the sector suffers from excessively high inventory levels (c. 18 months end-to-end) and slow response to changes in market demand [1] , [26] , [27] , [28] .
CASE STUDY ANALYSIS
The pharmaceutical cases that were chosen represent products at different stages of their product life cycle, have dissimilar product volume and pack complexity profiles, and varying transformation challenges if the alternative process supply network and business case is implemented.
The three cases for taking through the analytical process represent;  Annual volume ranges that span (1) <<100 tonnes, (2) mid-range volumes (200-300 tonnes), and (3) volumes substantially > 10,000 tonnes The rationale for each of the selected cases products is further defined in Figure 3 , with supporting drivers for change, reported in Table 2 .
For each of these products the stage-wise analysis process conducted and findings are described below;
(i) Identifying barriers and (system-level) opportunities to adopting alternative product-process technologies for specific cases
The first stage of the analysis considers the potential end-user markets where continuous processing technology might provide additional volume or variant opportunities, in terms of business and/or societal benefits. This may involve delivering unmet user needs (e.g. low volume, niche markets previously unviable) and/or operational variant flexibility benefits, or cost benefits through increased scale.
Figure 3 -Volume-product variety profiles for the three specific product-process cases
For each of the three cases, system level barriers and opportunities that might result from adopting more continuous processing are considered from multiple perspectives; new patient populations, government health service providers, and industrial network partners.
(ii) Sub-system identification and analysis; comparison with an end-to-end systems perspective
In this second stage of the analysis, 'current-state' configuration mapping and basic product-life cycle tools are used to identify the sub-systems across the total supply/value network. The following sub-systems were identified within the Pharmaceutical product sector; Clinical trial Supply Chain process; Primary and Secondary Manufacture, Packing and downstream Distribution.
The specific research questions to be addressed in terms of system optimisation, factors of analysis, and desired outcome across these subsystems were defined as follows;
Vo lume 100s of tonnes >10,000s of tonnes

Specific
Generic
• Volumes: Ranging from low volume, expensive, niche products c. 5-10 tonnes/annum to 50 tonnes/annum (->100 tonnes in some cases).
• Product variety: Number of drugs used is large.
Regimens are complex, with multiple fixed-dose combinations. Demand fragmentation common in small segments and niche markets
• Volumes: Stable demand profile likely to remain in the range of c. 200-300 tonnes/annum • Product Variety: Multiple combinations on the market, with potential for more to control resistance.
• Volumes: High volumes predicted to double to ~60,000 tonnes/annum by 2035 • Several generic brands on the market with offerings of 10-100 tonnes/month at low cost already available For each of the case product groups, technical experts were used to collate standard operational data, current and alternative/future processing scenarios, and wider 'societal-importance' considerations that may influence the reconfiguration opportunity. Societal importance is based on developing the case for delivering more affordable drugs, meeting unmet needs or addressing new patient populations..
The results from this stage of the analysis are set out in Table 2 below.
(iii) Alternative supply network scenario analysis/development
In Table 2 , an initial assessment of future/alternative processing models was conducted where alternative chemical process scenario analysis considered opportunities for more flow-through continuous processing.
These scenarios are then evaluated in terms of the 'delta' or relative benefits against key system level operational benefits that might emerge from continuous processing. This step in the process generates 'the delta' or potential step change possibilities in the key metric(s) or impact variable under consideration (see table 3 ) 220M [35] , projected to increase to over 500M by 2018 [36] 387M, of which 90% is Type 2 diabetes [43] Unmet needs Treatment regimes complex. Managing complexity and adherence [30] . Access cost for newer drugs.
Product Cost high to patient without subsidy. Significant security issues. High counterfeit rates in several countries [35] .
Growing prevalence in emerging markets, >590M patients by 2035 [43] . Affordability and access to treatment.
Affordability factors
High cost for new combination products. Older drugs for leastdeveloped countries <$1 per day [31] Subsidy levels, to enable consumer affordability are currently high at ~ 90% [37] . Global funding for malaria, US$2.3B (in 2011)
Major healthcare cost In 2014, expenditure reached US $612 billion [43] Operational Data Current process highly variable quality and very low yields (cultivation and extraction) and high waste (100s kg/kg output) [38] Current processes have high yields and purity (>95%) [47] Processing model Current Multi-stage batch. Opportunities to reduce cost [29] , No. of drugs / regimens complex [30] Plant extraction / purification and multi-stage batch [38] . Delivery performance poor [36] Very simple batch process. Low cost already available [47] Future Potential for continuous API and continuous secondary. Service improvement opportunities [34] Several alternative synthetic routes with improved kinetics enable continuous API processing [38] . Potential for continuous secondary processing [40] , [41] , [42] High probability to be amenable to continuous API [46] and alternative formulation process enables secondary continuous processing [48] Potential opportunity Evaluation summary of opportunities from continuous manufacturing Improved API control to enable new formulation opportunities. Potential for new combination products to improve adherence and treatment
Potential for improved quality and supply reliability, and to reduce overall product cost.
Reduced capital cost for increased capacity required. 
(iv) Systems Analysis Analytical Framework
The analytical framework presented in this paper examined the interactions between the sub-systems in Pharma for the three cases, representing dissimilar product examples to demonstrate the utility of the approach.
In this paper, limitations of space constrain the full graphical presentation of the comparative analysis. However, figures 4 and 5 set out impact variables for the three case products in terms of cycle time v. %inventory for primary/secondary processing and %Inventory v. service in terms of E2E supply respectively. In assessing the specific continuous interventions for the three cases presented and the potential scale of opportunities across the E2E supply chain [1] , significant reductions of up to 50%, in terms of cycle time (starting materials to packed product) and >65% reductions of inventory (within primes) are achievable. This, in turn, improves service levels to the patient through the emergence of more demand-driven supply models [1] . Figure 4 -Primary/secondary continuous processing -specific benefits for the 3 cases in terms of improved cycle time Figure 5 . E2E supply through continuous processing -specific benefits for the three cases in terms of inventory and service Table 4 summarises the analysis for continuous processing across the three case product groups, using the analytical framework in conjunction with considerations of business context and technological readiness.
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Case 3
• Benefits here in terms of % inventory (and management of E2E supply) as opposed to cycle times, given potential scale of future supply requirements
Case 2
• Current processes reliant on annual harvesting (c. 18 months) and batch processing.
• Opportunity for continuous synthesis and bioprocessing to significantly reduce overall leadtime to final product (from 10s of months to weeks) with significant implications for cycle time
Case 1
• Minimum batch size requirements have resulted in 8 month delays between an initial order and production for low volume, niche products • Continuous crystallisations of API, better particle size control, coupled with continuous formulation offer new ways of managing complexity of volume, combinations and SKU mixes -eliminating the batch size requirements • Significant opportunity to reduce overall cycle times by ~50%
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Service % on me in-full (%OTIF)
Continuous/future Case 3
• Continuous secondary processing to drive significant service level benefits through smaller footprints enabling local supply, closer-to-market
Case 2
• Continuous formulation increasing the bioavailability of APIs would significantly reduce inventory, number of SKUs and overall cost of goods.
• Alternative continuous processing-driven network design options are enabling potential for significant improvements in terms of supply, distribution, and improved security -reducing the 'pill burden', leading to better treatment adherence and service levels
Case 1
• Manufacturers tend not carry a lot of inventory to avoid undeliverable stock that may fall below e.g. country requirements.
• Suppliers instead postpone production until confidence exists that there is enough demand to merit production of a full batch.
• Continuous processing has the potential to improve service levels by promoting a true 'made-to-order' model -eliminating high %-based shelf-life requirements, production delays and potential for stock-outs
Ty pically > 90% to distributor Specifically,

Case 1 may be classed as having medium potential. Whilst there may be opportunities in continuous formulation and tableting processing due to high drug-loading and drug-switching requirements, there remains large uncertainty with respect to the direction future front-line therapies and specific product lifecycle.
 Case 2 has high potential with opportunities to reduce cost and inventory and improve supply chain security.
 Case 3 has the highest potential for a switch to continuous, with simpler chemistry and a significantly growing demand requiring more capacity From a systems integration perspective, all three cases benefit from more integrated flow-through processing. As supply network design typically promotes flow-through as a principle of operation, and that continuous processing also offers volume flexibility, especially for lower scale production activities, all the continuous processing scenarios score favourably against current batch operations.
DISCUSSION & CONCLUSIONS
This paper extends earlier conceptual developments [25] on the evaluation of continuous processing technologies by applying refined concepts to three specific cases that are being actively explored in the sector.
It first explores the relative attractiveness of continuous vs. batch, and sets out the key factors, from an operations/supply-chain perspective, that needs to be considered. These observations are 'generic' in nature but make the case that continuous should be more prevalent in practice than it has been (in addition to being inappropriate in certain instances). The second set of observations, presented here as part of the conclusions, refer to the specific case studies and are very specific in nature. The aim is to explore possible options, and only in specific cases can priorities be discussed or identified.
The analytical approach has been applied in three case studies within the pharmaceutical sector where continuous processing is being actively considered. The analysis identifies reconfiguration opportunities that are driven by alternative product-processing innovations using continuous processing. The three specific case product groups that were considered represent diverse product-patient categories, where continuous processing may benefit a range of new product and patient groups. We conclude that the cases have medium to high potential for continuous processing and that case 3 has the highest potential based on the factors of analysis. In the three cases analysed, the following assessments were generated.
 Case 1 -Anti-retrovirals (ARVs) case study: may be classed as having medium potential, with specific opportunities in continuous crystallisations to enable better API quality control (especially for high drug loading products). Similarly, advances in continuous formulation may support product portfolio complexity management and drug switching requirements. However, there remains large uncertainty with respect to the direction of future front-line therapies and specific product lifecycles.
Discussion: In their recent review paper, Ripin et al. present key procurement and supply chain issues that challenge the timely and reliable delivery of ARVs [2] . Here, the opportunities around continuous formulation confirm new ways of managing the high complexity of volumes, combinations and SKU mixes to enable significant cycle time reductions, given the increasing fragmentation of demand, forecasting inaccuracies, shelf-life requirements and high variety of combinations. The current formulary list for ARVs is wide-ranging and complex -with each regimen having multiple formulations, with single, double or triple fixed-dose combination options. Overall demand continues to be split into smaller and smaller entities, by chemical entity, leading to very low treatment volumes. In terms of these very specialised drugs, it is becoming more and more difficult for manufacturers to retain profitability [2] . The case is also presented where pooled demand from three sources is required in order to 'trigger' achievement of the minimum batch size requirements for the product. The process here is lengthy, where examples have been reported of 8-month delays between and initial order and the initial batch production run. It is feasible to eliminate this lead-time and improve security of supply, through adopting smaller volume runs through more continuous routes.
In addition to the extensive drug-switching requirements for HIV as part of treatment regimes, driving product variants and complexity, the high requirements on shelf-life and a rather atypical tender model (where market specific stock is made to contract order) means manufacturers will typically not carry a lot of inventory to avoid undeliverable stock that may fall below e.g. country requirements.
Service levels are artificially high (typically > 90% to distributor) as suppliers tend to postpone any production until confidence exists that there is enough demand to merit a full batch -often leading to delays, stock-outs and less than ideal service levels [2] . In summary, continuous processing has the potential to improve service levels by reducing % inventory, eliminating minimum batch size requirements and safety stocks -enabling a more 'made-to-order' contract model.

Case 2 -Anti-malarial Artemisinin Combination Therapies (ACTs) case study: has high potential, with opportunities to reduce cycle times and inventory, by adopting continuous processes that also reduce solvent use. Several competing technology developments are being considered with maturing technology readiness levels, which suggest promising routes to commercialisation are possible.
Discussion: The current batch process involves cultivation (e.g. planting, growing, harvesting), then extraction using solvents, which is costly, and poses safety, environmental and product quality risks [38] . The total cycle time from planting to shipping is normally in excess of 14 months. A bioprocessing route has also been developed and commercialised (and qualified as an alternative source for Case 2- through to pack and distribution -with the potential of reducing overall cycle times (raw materials to pack) to 10s of weeks [3] .
Advances in continuous formulation to increase the bioavailability of APIs would significantly help reduce overall cost of goods and improve treatment adherence. The 'pill burden' may be significantly reduced, thereby, maximising the impact of benefit for patients and health providers.
Alternative network design options, exploring new technologies (e.g. inkjet printing) with respect to pack design [26] , have a significant opportunity in terms of supply chain and distribution, improving security and enabling health agencies to access better data.
 Case 3 -Diabetes drug case study: has the highest potential for a switch to continuous granulation supporting smaller plant footprints with associated capital cost reductions. The simpler chemistry involved in this case study and a significantly growing demand (requiring more capacity), where volume projections suggest a doubling of demand by 2035; contribute to a potentially attractive batch-tocontinuous transformation agenda.
Discussion: Having uninterrupted supply offers downstream inventory improvement, in the case of case 3, as opposed to cycle time gains presented for cases 1 and 2. As demand continues to increase (double-digits year-on-year), there are significant benefits in terms of % inventory and the management of E2E supply -given the volume and scale flexibilities afforded by continuous processing [1] , [27] , [28] .
The case studies are exploratory in nature and seek to demonstrate a methodology for identifying potential opportunity areas. The analysis suggests that the methodology can help to reveal reconfiguration opportunities that support re-integration of these sub-systems and deliver enhanced business performance that can also have societal benefits. In reviewing the assessments emerging from the analysis, the discussions above suggest the initial conclusions from this study are broadly supported. This further underpins the conclusions from the analytical approach set out above.
In conclusion, previous research studies confirm that many industrial systems comprise of semi-independent sub-systems that have evolved over extended time periods but have then become part-disconnected, operating as silos of activity with independent governance and coordination mechanisms [17] , [25] . In many cases, the regulatory frameworks 'lock-in' this structural development. An analytical framework, applicable to multiple industrial contexts is presented and applied which considers reconfiguration opportunities that adopt a systems perspective rather than incremental optimisation at the sub-system level. At a broader level, the study identifies the potential to reconfigure and re-integrate sub-systems by enabling a deeper understanding of the drivers of, and interactions between, the main sub-systems that make up complex, multi-tier supply chains.
LIMITATIONS AND FUTURE WORK
The work is part of an on-going research agenda that seeks to develop next generation Pharmaceutical supply chains. This involves extending the preliminary analysis conducted for selected patient populations and productprocess archetypes identified as having attractive business/value propositions and promising technological feasibility. The application of the methodology in three exploratory cases is used to demonstrate utility and some level of generalisability. Further case studies would indeed be expected (and are planned) as part of an extended testing regime. Consideration of the behavioural changes and dynamic capabilities required to make the transformation to continuous processing manufacturing models will be developed as part of future activity.
